SCHEMBL22018823

SCHEMBL22018823

O=C(Nc1cnc2c(c1-c1ccccccccc1)CCC2)c1ccccccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
TP53 P04637 4/20 0.48
KDR P35968 2/20 0.46
POLB P06746 4/20 0.45
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
ALDH1A1 P00352 1/20 0.45
SCD O00767 1/20 0.42
HPGD P15428 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC3 O15379 1/20 0.42
MAPK1 P28482 1/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ESR2 Q92731 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NTRK1 P04629 2/20 0.41
P4HTM Q9NXG6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22019115 0.81 HDAC3 (0.49) SMN1; SMN2RAB9ANPC1ALDH1A1HPGD
SCHEMBL20368721 0.73 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGDMAPK1LMNA
SCHEMBL18779343 0.72 LDHA (0.44) SMN1; SMN2POLBALDH1A1HPGDLMNA
SCHEMBL19059699 0.72 TP53 (0.39) SMN1; SMN2TP53POLBRAB9ANPC1
SCHEMBL22853731 0.72 KDR (0.39) SMN1; SMN2KDRRAB9ANPC1ALDH1A1
SCHEMBL18779347 0.70 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGDMAPK1LMNA
SCHEMBL28987534 0.68 L3MBTL1 (0.72) SMN1; SMN2TP53POLBRAB9ANPC1
SCHEMBL18399566 0.68 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL4910048 0.68 AURKB (0.56) SMN1; SMN2TP53KDRRAB9ANPC1
SCHEMBL27625287 0.66 HDAC2 (0.70) TP53POLBRAB9ANPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORPORATION 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200155527-A1 THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 SMN1; SMN2 3837/4885TP53 578/4885KDR 1554/4885
US-10828290-B2 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors PIM2, PIM1, PIM3 SMN1; SMN2 3837/4885TP53 578/4885KDR 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.